Pharmacology Newswire (Page 5)

Pharmacology Newswire (Page 5)

Comprehensive Real-Time News Feed for Pharmacology. (Page 5)

Results 81 - 100 of 27,213 in Pharmacology

  1. Temple scientists discover structural clues to calcium regulation in cellsRead the original story w/Photo

    Wednesday Aug 24 | EurekAlert!

    ... Other researchers on the study include Samuel K. Lee and Peter B. Stathopulos, Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Santhanam Shanmughapriya, Zhiwei Dong, ... 1 comment

  2. Armetheon Announces Positive Results Of Pharmacokinetics Study Of Tecarfarin Versus WarfarinRead the original story

    Wednesday Aug 24 | BioSpace

    Tecarfarin's pharmacokinetics were not significantly affected by severe renal impairment, whereas warfarin clearance was substantially reduced and a large increase in half-life was seen. Despite warfarin being the treatment of choice for decades for patients requiring anticoagulation, physicians have also recognized the limitations of warfarin, which can result in a significant portion of patients being poorly controlled.

    Comment?

  3. Crown Bioscience Expands CVMD Leadership TeamRead the original story

    Wednesday Aug 24 | BioSpace

    Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has announced the appointment of Amar Thyagarajan, Ph.D., and Sandeep Sinha, Ph.D., to its team. Thyagarajan joins CrownBio as the associate director of product marketing and strategy.

    Comment?

  4. Mylan And BioCon Announce Regulatory Submission For Proposed...Read the original story

    Wednesday Aug 24 | BioSpace

    This is the second biosimilar submission developed by the partnership that has been accepted for review in Mylan and Biocon, which have co-developed this proposed biosimilar, anticipate that this may be the first MAA for a Trastuzumab biosimilar accepted by the EMA for review. This filing includes analytical, functional and pre-clinical data, as well as results from the pharmacokinetics and confirmatory efficacy/safety global clinical trials for Trastuzumab.

    Comment?

  5. Hamilton Thorne, Inc. Reports 7% Sales Increase For The Quarter Ended June 30, 2016Read the original story

    Wednesday Aug 24 | BioSpace

    Hamilton Thorne Ltd. , a leading provider of precision laser devices and advanced image analysis systems for the assisted reproductive technologies and developmental biology research markets, today reported operational and financial results for the quarter and six months ended June 30, 2016. Hamilton Thorne reported total sales of $2.4 million for the quarter ended June 30, 2016, a 7% increase versus the prior year.

    Comment?

  6. Advanced Clinical Laboratory Solutions Signs Contract Providing...Read the original story

    Wednesday Aug 24 | BioSpace

    Advanced Clinical Laboratory Solutions, Inc. , an independent clinical laboratory specializing in clinical toxicology and pharmacogenetics that provides convenient, high-quality testing services and accurate, timely test results to patients, physicians and medical centers across the country, has signed a clinical laboratory services contract effective Aug. 1, 2016, with POMCO . POMCO is one of the nation's largest third-party administrators integrating customized services to develop comprehensive, cost-effective solutions "We look forward to serving POMCO's participating physicians who prefer using a single, high-quality, full-service laboratory.

    Comment?

  7. Data Aggregation, Curation and Modeling Approaches to Deliver...Read the original story

    Thursday Aug 25 | U.S. Environmental Protection Agency

    EPA Home A Science Inventory A Data Aggregation, Curation and Modeling Approaches to Deliver Prediction Models to Support Computational Toxicology at the US EPA Data Aggregation, Curation and Modeling Approaches to Deliver Prediction Models to Support Computational Toxicology at the US EPA Williams, A., K. Mansouri, T. Martin, Chris Grulke, J. Wambaugh, R. Judson, G. Patlewicz, I. Shah, AND A. Richard. Data Aggregation, Curation and Modeling Approaches to Deliver Prediction Models to Support Computational Toxicology at the US EPA .

    Comment?

  8. Atomic level analysis reveals how two classes of calcium channel blockers produce different effectsRead the original story w/Photo

    Thursday Aug 25 | Medical News

    ... binding sites. UW Medicine researchers William A. Catterall, University of Washington professor and chair of pharmacology, and Ning Zheng, UW professor of pharmacology and investigator of the Howard Hughes Medical Institute, headed the project. The ...

    Comment?

  9. Visterra to Present New Clinical Results of VIS410 at the Options IX for...Read the original story w/Photo

    Thursday Aug 25 | Freshnews

    The data presented at the Options IX Conference will detail efficacy, resistance testing, and pharmacokinetic results from a Phase 2a influenza viral challenge study of VIS410. Data also will be presented that demonstrates that, in preclinical mouse models, VIS410 did not cause antibody-dependent enhancement, which is a phenomena where non-neutralizing antibodies can bind to the virus and enhance the disease.

    Comment?

  10. Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.Read the original story

    Wednesday Aug 24 | CiteULike

    Cytochrome P450 2C8 is a drug metabolizing enzyme of major importance. The lipid-lowering drug gemfibrozil has been identified as a strong inhibitor of CYP2C8 in vivo.

    Comment?

  11. Failed news company Al Jazeera now peddling Monsanto propagandaRead the original story w/Photo

    Wednesday Aug 24 | NewsTarget.com

    If you wanted to fail in media post-9/11 America, probably one of the best ways to achieve that would be to have your network funded by the oil-rich dictatorial sheikdom of Qatar , a nation that also lavishly funds Islamic terrorist and extremist groups like Hamas and the Muslim Brotherhood . Another way to turn off a massive and growing segment of the American viewing public would be for the same network to get in bed with a serial environmental offender, namely Monsanto , the world's largest maker of genetically modified seeds and foods.

    Comment?

  12. Led by Former Genentech Execs, Denali Banks $130 Million, Initiates Trial and Discloses DealsRead the original story w/Photo

    Wednesday Aug 24 | BioSpace

    "We continue to progress toward our ultimate goal of helping patients who suffer from debilitating neurodegenerative disease," said Dr. Watts. Denali is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.

    Comment?

  13. NeuroDerm Announces Second Quarter 2016 Financial Results and Provides Corporate UpdateRead the original story

    Jun 30, 2016 | P&T Community

    NeuroDerm Ltd. , a clinical stage pharmaceutical company developing drugs for central nervous system diseases, today announced financial results for the second quarter ended June 30, 2016 and provided a corporate update. "We have been very productive in recent months advancing our clinical programs and moving closer toward our goal of providing a less invasive, continuous levodopa delivery treatment option for patients suffering from Parkinson's disease," said Oded Lieberman, PhD, CEO of NeuroDerm.

    Comment?

  14. Correction [Corrections]Read the original story

    Jun 27, 2016 | Circulation

    In the article by Canonico et al , which published online on June 2, 2016, and appeared in the July 2016 issue of the journal, a correction was needed. On page 1734, the affiliation for Dr Tubert-Bitter, "Universite Paris-Saclay, Univ.

    Comment?

  15. Pharmacist Stan Dobrzanski retires after four decades at BRIRead the original story

    Wednesday Aug 24 | Thetelegraphand Argus

    HOSPITAL pharmacist Stan Dobrzanski has prescribed himself a long and happy retirement after almost 40 years at Bradford Royal Infirmary . Mr Dobrzanski's career has seen lots of changes over the years and he has been instrumental in making many of them happen.

    Comment?

  16. Calcium channel blockers caught in the act at atomic levelRead the original story w/Photo

    Wednesday Aug 24 | Biology News Net

    ... binding sites. UW Medicine researchers William A. Catterall, University of Washington professor and chair of pharmacology, and Ning Zheng, UW professor of pharmacology and investigator of the Howard Hughes Medical Institute, headed the project. The ...

    Comment?

  17. CPRIT awards $9.6 million for UTSW projects in cancer treatments, screening, and genetics researchRead the original story

    Wednesday Aug 24 | PressReleasePoint

    ... said Dr. Melanie Cobb , Interim Director of the Harold C. Simmons Comprehensive Cancer Center, Professor of Pharmacology and holder of the Jane and Bill Browning, Jr. Chair in Medical Science. "This effort includes a wide range of projects, from ...

    Comment?

  18. TeaCrine poised to rev up market size post self-affirmed GRASRead the original story w/Photo

    Wednesday Aug 24 | NutraIngredients-USA

    Compound Solutions, the company behind nature identical theacrine called TeaCrine, is aiming to make cognitive plus energy products more mainstream. "The market has been dominated by 'energy' for nearly 15 years.

    Comment?

  19. Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice [Basic Sciences]Read the original story

    Wednesday Aug 24 | Circulation

    From the Division of Cardiovascular Medicine, Department of Medicine , Department of Pharmacology , and Department of Pathology Microbiology and Immunology , Vanderbilt University, Nashville, TN; Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University, Columbus ; Transplant Institute, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA ; School of Medicine, Deakin University ; Immunology Research Centre, St. Vincent's Hospital ; and Department of Medicine, University of Melbourne, Victoria, Australia .

    Comment?

  20. Visterra to Present New Clinical Results of VIS410 at the Options IX...Read the original story

    Wednesday Aug 24 | Information Technology

    Visterra, Inc., a clinical-stage biotechnology company, today announced that two posters and one oral presentation related to the Company's lead product candidate, VIS410, a novel monoclonal antibody in development for the treatment of seasonal and pandemic influenza A, will be presented at the Options IX for the Control of Influenza Conference in Chicago, Illinois, on August 24 - 28, 2016. The data presented at the Options IX Conference will detail efficacy, resistance testing, and pharmacokinetic results from a Phase 2a influenza viral challenge study of VIS410.

    Comment?